source
- Ipsen executive urges scientists to look beyond first results to achieve patient impactPhilippe Lopes-Fernandes, executive vice president and chief business officer at Ipsen, reflects on how scientific progress often requires moving past an initial finding. He notes that a result can…
- Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T assetAside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.